GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 13, Issue 11, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-14
DOI
10.1038/s41419-022-05419-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Allele-specific alternative splicing and its functional genetic variants in human tissues
- (2021) Kofi Amoah et al. GENOME RESEARCH
- GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers
- (2020) Wey-Ran Lin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations
- (2020) Xiao-Zhen Zhang et al. Cancers
- COX5B-Mediated Bioenergetic Alteration Regulates Tumor Growth and Migration by Modulating AMPK-UHMK1-ERK Cascade in Hepatoma
- (2020) Yu-De Chu et al. Cancers
- Allele-specific binding of RNA-binding proteins reveals functional genetic variants in the RNA
- (2019) Ei-Wen Yang et al. Nature Communications
- The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine
- (2019) Yu-De Chu et al. Cell Death & Disease
- O-linked mucin-type glycosylation in breast cancer
- (2018) Joy M. Burchell et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- EFEMP2 Mediates GALNT14-Dependent Breast Cancer Cell Invasion
- (2018) Tao Zuo et al. Translational Oncology
- GALNT14 Involves the Regulation of Multidrug Resistance in Breast Cancer Cells
- (2018) Jinshuai Shan et al. Translational Oncology
- Emergence of oncogenic‐enhancing hepatitis B virus X gene mutants in patients receiving suboptimal entecavir treatment
- (2018) Chih‐Lang Lin et al. HEPATOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A novel function for the DEAD-box RNA helicase DDX-23 in primary microRNA processing in Caenorhabditis elegans
- (2016) Yu-De Chu et al. DEVELOPMENTAL BIOLOGY
- Alternative splicing modulated by genetic variants demonstrates accelerated evolution regulated by highly conserved proteins
- (2016) Yun-Hua Esther Hsiao et al. GENOME RESEARCH
- GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization
- (2016) Kung-Hao Liang et al. PHARMACOGENOMICS
- GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment
- (2016) Ki-Hoon Song et al. Nature Communications
- Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology
- (2013) Catharina Steentoft et al. EMBO JOURNAL
- A single nucleotide polymorphism on theGALNT14gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma
- (2013) Chau-Ting Yeh et al. INTERNATIONAL JOURNAL OF CANCER
- Prohibitin-2 Binding Modulates Insulin-like Growth Factor-binding Protein-6 (IGFBP-6)-induced Rhabdomyosarcoma Cell Migration
- (2013) Ping Fu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy
- (2013) Jun Cheng et al. MOLECULAR CARCINOGENESIS
- The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13
- (2013) RANRAN WANG et al. ONCOLOGY REPORTS
- GALNT14SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC
- (2011) Kung-Hao Liang et al. PHARMACOGENOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation